Arcellx (ACLX) said Wednesday that a phase 2 study of anitocabtagene autoleucel showed that patients with relapsed or refractory multiple myeloma demonstrated an overall response rate of 97%.
The results also showed a complete response/stringent complete response rate of 68% and a very good partial response or higher rate of 85%, based on International Myeloma Working Group criteria as investigator-assessed, the company said.
Arcellx said no delayed or non-immune effector cell-associated neurotoxicity syndrome neurotoxicities have been observed to date with the therapy.
The company said it plans a commercial launch for the therapy in 2026.
Shares were up 6.2% in recent trading.
Price: 61.86, Change: +3.61, Percent Change: +6.20
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。